BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 22277260)

  • 1. Protein dynamics at Eph receptor-ligand interfaces as revealed by crystallography, NMR and MD simulations.
    Qin H; Lim L; Song J
    BMC Biophys; 2012 Jan; 5():2. PubMed ID: 22277260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unique structure and dynamics of the EphA5 ligand binding domain mediate its binding specificity as revealed by X-ray crystallography, NMR and MD simulations.
    Huan X; Shi J; Lim L; Mitra S; Zhu W; Qin H; Pasquale EB; Song J
    PLoS One; 2013; 8(9):e74040. PubMed ID: 24086308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crystal structure and NMR binding reveal that two small molecule antagonists target the high affinity ephrin-binding channel of the EphA4 receptor.
    Qin H; Shi J; Noberini R; Pasquale EB; Song J
    J Biol Chem; 2008 Oct; 283(43):29473-84. PubMed ID: 18708347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insights into Eph receptor tyrosine kinase activation from crystal structures of the EphA4 ectodomain and its complex with ephrin-A5.
    Xu K; Tzvetkova-Robev D; Xu Y; Goldgur Y; Chan YP; Himanen JP; Nikolov DB
    Proc Natl Acad Sci U S A; 2013 Sep; 110(36):14634-9. PubMed ID: 23959867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sizes of interface residues account for cross-class binding affinity patterns in Eph receptor-ephrin families.
    Guo FY; Lesk AM
    Proteins; 2014 Mar; 82(3):349-53. PubMed ID: 24105818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small molecules can selectively inhibit ephrin binding to the EphA4 and EphA2 receptors.
    Noberini R; Koolpe M; Peddibhotla S; Dahl R; Su Y; Cosford ND; Roth GP; Pasquale EB
    J Biol Chem; 2008 Oct; 283(43):29461-72. PubMed ID: 18728010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural plasticity of eph receptor A4 facilitates cross-class ephrin signaling.
    Bowden TA; Aricescu AR; Nettleship JE; Siebold C; Rahman-Huq N; Owens RJ; Stuart DI; Jones EY
    Structure; 2009 Oct; 17(10):1386-97. PubMed ID: 19836338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural characterization of the EphA4-Ephrin-B2 complex reveals new features enabling Eph-ephrin binding promiscuity.
    Qin H; Noberini R; Huan X; Shi J; Pasquale EB; Song J
    J Biol Chem; 2010 Jan; 285(1):644-54. PubMed ID: 19875447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of Eph receptor-ephrin ligand interaction by tea polyphenols.
    Noberini R; Koolpe M; Lamberto I; Pasquale EB
    Pharmacol Res; 2012 Oct; 66(4):363-73. PubMed ID: 22750215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The first identification of complete Eph-ephrin signalling in ctenophores and sponges reveals a role for neofunctionalization in the emergence of signalling domains.
    Krishnan A; Degnan BM; Degnan SM
    BMC Evol Biol; 2019 Apr; 19(1):96. PubMed ID: 31023220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eph/Ephrin signaling regulates the mesenchymal-to-epithelial transition of the paraxial mesoderm during somite morphogenesis.
    Barrios A; Poole RJ; Durbin L; Brennan C; Holder N; Wilson SW
    Curr Biol; 2003 Sep; 13(18):1571-82. PubMed ID: 13678588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure of the EphB6 receptor ectodomain.
    Mason EO; Goldgur Y; Robev D; Freywald A; Nikolov DB; Himanen JP
    PLoS One; 2021; 16(3):e0247335. PubMed ID: 33770085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinctive binding of three antagonistic peptides to the ephrin-binding pocket of the EphA4 receptor.
    Lamberto I; Qin H; Noberini R; Premkumar L; Bourgin C; Riedl SJ; Song J; Pasquale EB
    Biochem J; 2012 Jul; 445(1):47-56. PubMed ID: 22489865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A disalicylic acid-furanyl derivative inhibits ephrin binding to a subset of Eph receptors.
    Noberini R; De SK; Zhang Z; Wu B; Raveendra-Panickar D; Chen V; Vazquez J; Qin H; Song J; Cosford ND; Pellecchia M; Pasquale EB
    Chem Biol Drug Des; 2011 Oct; 78(4):667-78. PubMed ID: 21791013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and structural analysis of a nanomolar cyclic peptide antagonist for the EphA4 receptor.
    Lamberto I; Lechtenberg BC; Olson EJ; Mace PD; Dawson PE; Riedl SJ; Pasquale EB
    ACS Chem Biol; 2014 Dec; 9(12):2787-95. PubMed ID: 25268696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamic principle for designing antagonistic/agonistic molecules for EphA4 receptor, the only known ALS modifier.
    Qin H; Lim LZ; Song J
    ACS Chem Biol; 2015 Feb; 10(2):372-8. PubMed ID: 25334011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural, stability, dynamic and binding properties of the ALS-causing T46I mutant of the hVAPB MSP domain as revealed by NMR and MD simulations.
    Lua S; Qin H; Lim L; Shi J; Gupta G; Song J
    PLoS One; 2011; 6(11):e27072. PubMed ID: 22069488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NMR structure and dynamics of human ephrin-B2 ectodomain: the functionally critical C-D and G-H loops are highly dynamic in solution.
    Ran X; Qin H; Liu J; Fan JS; Shi J; Song J
    Proteins; 2008 Aug; 72(3):1019-29. PubMed ID: 18300229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Global evaluation of Eph receptors and ephrins in lung adenocarcinomas identifies EphA4 as an inhibitor of cell migration and invasion.
    Saintigny P; Peng S; Zhang L; Sen B; Wistuba II; Lippman SM; Girard L; Minna JD; Heymach JV; Johnson FM
    Mol Cancer Ther; 2012 Sep; 11(9):2021-32. PubMed ID: 22807579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crystal structure of the ligand-binding domain of the promiscuous EphA4 receptor reveals two distinct conformations.
    Singla N; Goldgur Y; Xu K; Paavilainen S; Nikolov DB; Himanen JP
    Biochem Biophys Res Commun; 2010 Sep; 399(4):555-9. PubMed ID: 20678482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.